Supplementary Appendix S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Key Points

FOXC1 expression is a significant predictor of capecitabine efficacy in patients with triple-negative breast cancer.
The analysis shows that higher FOXC1 levels correlate with better treatment outcomes using capecitabine.
Findings stem from the GEICAM_CIBOMA trial, which involved diverse patient demographics receiving treatment.
These results highlight the importance of personalized treatment strategies in triple-negative breast cancer management.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Analysis reveals FOXC1 expression predicts capecitabine response in triple-negative breast cancer patients, suggesting its potential as a biomarker.

Nonauthor Collaborators

No takes yet. Share an insight, caveat, or question.

Rojo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share